arrow
F

Filippo Montemurro

f hoffmann la roche
H指数:48
被引数:9,467

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer
2024-12-180
OA
Gender minorities in breast cancer - Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients

乳腺癌中的性别少数群体-临床试验入组差异: 关注男性,跨性别和性别多样化的患者

BREAST
IF7.9
2024-06-011
OAAI
Impact of Body Mass Index (BMI) on the efficacy of different adjuvant chemotherapy schedules in patients with breast cancer: analysis from the randomized phase III GIM2 trial
2024-05-020
PRE
HER2 immunohistochemistry (IHC) expression in HER2-positive (HER2pos) metastatic breast cancer (mBC): clinical and prognostic differences between IHC 2+and IHC 3+populations
2024-05-020
PRE
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
2023-06-083
OA
Serum thymidine kinase activity in patients with HR- positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial

接受ribociclib和来曲唑治疗的HR阳性/HER2-negative晚期乳腺癌患者的血清胸苷激酶活性: 前瞻性BioItaLEE试验的结果

2023-06-015
PRE
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

根据晚期乳腺癌国际共识指南的内分泌耐药/敏感性分类的预后和临床影响: 来自Mammella InterGruppo (MIG) 和Gruppo Italiano Mammella (GIM) 研究的个体患者水平分析

2023-05-017
OAAI
Assessing the clinico-pathological characteristics of HER2 positive metastatic breast cancer patients experiencing radiologic complete response in a nationwide cohort
2023-03-010
PRE